Publication date: December 2026 Source: Fitoterapia, Volume 195 Author(s): Ki-Shuk Shim, Hye Jin Kim, Su-Jin Baek, Dong Ryun Gu, Yu Jin Kim, Seong Cheol Kim, Sungwook Chae, Taesoo Kim, Ki Mo Kim
Desoxo-narchinol A and water extract of Nardostachys jatamansi ameliorate house dust mite-induced atopic dermatitis by regulating Nrf2/HO-1 signaling. // Fitoterapia. – URL: https://www.sciencedirect.com/science/article/pii/S0367326X26004569?dgcid=rss_sd_all
Desoxo-narchinol A and water extract of Nardostachys jatamansi ameliorate house dust mite-induced atopic dermatitis by regulating Nrf2/HO-1 signaling. Fitoterapia. https://www.sciencedirect.com/science/article/pii/S0367326X26004569?dgcid=rss_sd_all
“Desoxo-narchinol A and water extract of Nardostachys jatamansi ameliorate house dust mite-induced atopic dermatitis by regulating Nrf2/HO-1 signaling.” Fitoterapia.
@article{article46107,
title = {Desoxo-narchinol A and water extract of Nardostachys jatamansi ameliorate house dust mite-induced atopic dermatitis by regulating Nrf2/HO-1 signaling},
journal = {Fitoterapia},
url = {https://www.sciencedirect.com/science/article/pii/S0367326X26004569?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...